Background An urgent need exists for antibiotics to treat infections caused by carbapenem-
resistant Acinetobacter baumannii–calcoaceticus complex (ABC). Sulbactam–durlobactam …

Sulbactam-durlobactam is a β-lactam-β-lactamase inhibitor combination designed to treat
serious Acinetobacter baumannii-calcoaceticus complex (ABC) infections, including …

Objectives This study aimed to compare the efficacy and safety of combination therapy with
high-dose sulbactam or colistin with additional antibacterial agents for treating multidrug …

Acinetobacter baumannii-calcoaceticus complex (ABC) organisms cause severe infections
that are difficult to treat due to preexisting antibiotic resistance. Sulbactam-durlobactam …

BACKGROUND: A number of studies have reported on the effectiveness of sulbactam-
based therapies for Acinetobacter baumannii infection; however, there is little evidence that …

Infections caused by multidrug‐resistant Acinetobacter baumannii have become a
therapeutic challenge for clinicians worldwide. Although colistin and tigecycline have been …

Objectives To comprehensively compare and rank the efficacy and safety of available
treatment options for patients with MDR and XDR Acinetobacter baumannii (AB) infection …

Acinetobacter baumannii-calcoaceticus complex (ABC) causes severe infections that are
difficult to treat due to pre-existing antibiotic resistance. Sulbactam-durlobactam (SUL-DUR) …

Objectives To evaluate the activity of the novel broad-spectrum serine β-lactamase inhibitor
durlobactam (ETX2514) combined with sulbactam against global isolates of carbapenem …

Background Acinetobacter baumannii is a leading cause of healthcare-associated infections
worldwide, due to both its persistence in the hospital setting and ability to acquire high levels …